No medication has been approved by any regulatory agency specifically for the treatment of borderline personality disorder (BPD). Despite this, more than 80 percent of people diagnosed with BPD are on at least one psychotropic drug, and roughly half take three or more at the same time.1PubMed Central. Pharmacological Management of Borderline Personality Disorder and Common Comorbidities That gap between the evidence and what actually happens in clinics is one of the most striking disconnects in modern psychiatry, and understanding it matters if you or someone you care about is navigating a BPD diagnosis.
Why No Drug Has Been Approved
The short explanation is that BPD is not a single-target condition. It involves emotional instability, impulsive behavior, distorted self-image, and turbulent relationships, and those features arise from interacting biological and psychological systems rather than a single neurotransmitter imbalance that a pill can correct. Researchers have studied serotonin dysfunction, altered GABA signaling, and other neurochemical patterns in people with BPD, but these findings have not translated into a clear pharmacological target the way dopamine pathways did for schizophrenia or serotonin reuptake did for major depression.2PubMed. Serotonin, personality and borderline personality disorder
The clinical trials themselves have also been a problem. Most studies of medications in BPD have been small, short, and used a wide variety of outcome measures, making it hard to pool results or draw firm conclusions.3PubMed Central. Pharmacological Management of Borderline Personality Disorder and Common Comorbidities A systematic review and meta-analysis of the available evidence found that second-generation antipsychotics, anticonvulsants, and antidepressants could not consistently reduce overall BPD severity across studies.4PubMed Central. Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis That does not mean every drug was useless for every symptom, but none cleared the bar needed for regulatory approval as a BPD treatment.
What Gets Prescribed Anyway
Even without approval, clinicians routinely prescribe from three broad drug classes for people with BPD. Every major clinical guideline acknowledges that medications can play some role, though the nature and extent of that role is disputed between guidelines.5PubMed Central. Clinical practice guidelines for the treatment of borderline personality disorder: a systematic review of best practice in anticipation of MAiD MD-SUMC The American Psychiatric Association’s guidelines, published in 2001 and never formally updated, are comparatively optimistic about using SSRIs, mood stabilizers, and antipsychotics as add-on treatments.6PubMed. A comparison of UK and US guidelines for drug treatment in borderline personality disorder UK and Australian guidelines tend to be more cautious, emphasizing psychotherapy as the core treatment and warning against routine prescribing.
Antipsychotics
Second-generation antipsychotics like quetiapine, olanzapine, and aripiprazole are among the most commonly prescribed drugs for BPD. The rationale is that they may help with anger, brief psychotic-like symptoms, paranoia, and anxiety. In practice, the evidence is inconsistent. A review of the available studies found that while these drugs might target depression, anxiety, anger, and paranoia in BPD, they failed to reliably improve any of those symptoms across studies.7PubMed Central. Second-generation antipsychotic use in borderline personality disorder: What are we targeting? Earlier work suggested a potential role for atypical antipsychotics in treating psychotic symptoms and impulsivity, but observation periods in most studies were short and dosages were low.8PubMed. Treatment of borderline personality disorder with atypical antipsychotic drugs The meta-analytic picture is that antipsychotics had little effect on specific BPD symptoms but did improve general psychiatric symptoms, a distinction that matters when you are trying to figure out what exactly they are doing.9PubMed Central. Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis
Mood Stabilizers and Anticonvulsants
Mood stabilizers represent the drug class with some of the more promising, though still limited, evidence. Lamotrigine in particular has drawn attention for its potential to stabilize mood and reduce emotional dysregulation and impulsivity in BPD, with a safety profile comparable to other options.10PubMed Central. The Therapeutic Role of Lamotrigine in Borderline Personality Disorder: A Comprehensive Review of Outcomes, Mechanisms, and Treatment Strategies Topiramate and valproate have also shown some benefit for affective symptoms and impulsive behavioral problems.11PubMed. Pharmacotherapy of borderline personality disorder: a systematic review for publication purpose The broader meta-analytic view, though, classifies this evidence as low-certainty and notes it is mostly limited to individual studies rather than being replicated across multiple trials.12PubMed Central. Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis
Antidepressants
SSRIs and other antidepressants are prescribed frequently for BPD, partly because depression and BPD overlap so often and partly because the APA guidelines from 2001 supported their use. The evidence, however, has not held up well. Meta-analysis provides little support for antidepressant medication in BPD outside episodes of major depression.13PubMed Central. Borderline personality disorder: current drug treatments and future prospects If you have BPD and a co-occurring depressive episode, an antidepressant may help the depression. But for the emotional instability, impulsivity, and relationship difficulties that define BPD itself, antidepressants have not shown consistent benefits.
The Polypharmacy Problem
One of the most concerning patterns in BPD treatment is how many medications accumulate over time. A national study using New Zealand’s health databases found that half of medicated BPD patients were taking three or more psychotropic drugs in 2014, and this rose to about 56 percent by 2019. The proportion on seven or more psychotropics climbed from roughly 8 to 11 percent over that same period.14PubMed Central. Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand’s national databases Quetiapine was the single most commonly dispensed drug, given to about 54 percent of medicated patients. Lorazepam prescribing showed a particularly large increase, nearly doubling over five years.15PubMed Central. Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand’s national databases
This pattern develops for understandable reasons. BPD symptoms are severe and fluctuating. A clinician facing a patient in acute distress may add a medication to address an immediate crisis, and then the crisis passes but the medication stays. New symptoms emerge, another drug gets added, and over months or years the regimen grows without anyone stepping back to ask whether each medication is still earning its place. Guidelines explicitly warn that polypharmacy and the use of medications with overdose risk should be avoided in BPD.16PubMed Central. Pharmacological Management of Borderline Personality Disorder and Common Comorbidities
Overdose Risk and Safety
The prescribing hazards go beyond side effects. BPD is associated with impulsive self-harm and suicidal behavior, so the very medications prescribed to help can become instruments of harm. A retrospective study of overdose presentations found that the majority of agents taken in overdose were prescribed medications. Benzodiazepines and antipsychotics were the drug classes most commonly involved, and quetiapine alone accounted for about 39 percent of cases with severe toxicity, defined as coma or dangerously low blood pressure.17PubMed Central. Psychotropic Medication Overdose and off-label psychotropic prescribing in patients with borderline personality disorder: A retrospective series This creates a paradox: quetiapine is the most frequently prescribed psychotropic for BPD, and also one of the most dangerous in overdose for this population.
Australian prescribing guidance recommends using single drugs in limited quantities for limited periods to minimize these risks.18PubMed Central. Prescribing and borderline personality disorder That advice is straightforward but rarely followed in practice, as the polypharmacy data make clear.
The Placebo Puzzle
An underappreciated complication in BPD medication research is the strength of placebo response. An analysis of the placebo arms of randomized controlled trials found that patients receiving placebo showed significant symptom improvement on their own.19Journal of Clinical Psychopharmacology. Antipsychotics, Antidepressants, Anticonvulsants, and Placebo on the Symptom Dimensions of Borderline Personality Disorder This is not unique to BPD; psychiatric conditions generally have meaningful placebo responses. But it is especially relevant here because BPD symptoms naturally wax and wane, and people tend to enter studies during crisis periods. By the time the study ends, symptoms may have improved regardless of what pill they received. That makes it genuinely hard to separate a drug’s real pharmacological effect from the natural course of the condition, and it helps explain why so many trials show modest or inconsistent benefits.
When Other Diagnoses Complicate the Picture
Most people with BPD also have at least one other psychiatric diagnosis, whether that is depression, PTSD, ADHD, an eating disorder, or bipolar disorder. The overlap with bipolar disorder is particularly tricky because the two conditions share features like mood instability and impulsivity, and the treatment approaches differ. When BPD and bipolar disorder coexist, stabilization becomes harder. One study found that only a quarter of patients with both conditions achieved clinical stabilization, compared with about three-quarters of those with bipolar disorder alone. The few who did stabilize often took more than 95 weeks, compared with a median of 35 weeks for the bipolar-only group.20PubMed. Acute treatment outcomes in patients with bipolar I disorder and co-morbid borderline personality disorder receiving medication and psychotherapy The comorbid group also required significantly more medications per year and had high dropout rates.
More broadly, BPD comorbidity appears to hamper treatment effectiveness in bipolar patients, though some evidence suggests that mood stabilizers can still achieve clinical response even when BPD is present.21International Clinical Psychopharmacology. Does the comorbidity of borderline personality disorder affect the response to treatment in bipolar patients? The practical takeaway is that if your medication doesn’t seem to be working and you have BPD alongside another condition, the BPD itself may be part of the reason. That does not mean medication is hopeless, but it does mean expectations should be calibrated accordingly.
What Patients Actually Report
The clinical literature focuses on symptom scores and trial outcomes, but patient accounts reveal a different dimension of the medication experience. In one study of treatment adherence, the most common reasons people with BPD stopped taking their medications were side effects (reported by about 53 percent), dissatisfaction with the therapist (about 40 percent), and fear of becoming dependent on medication (also about 40 percent).22PubMed Central. Factors associated with pharmacological and psychotherapy treatments adherence in patients with borderline personality disorder Side effects were not minor annoyances. For many people, they were the central experience of being medicated, shaping their sense of agency and selfhood.
Qualitative research has captured how people with BPD experience medication as something simultaneously necessary and destabilizing, protective and punitive. Participants in one study described medication less as a targeted treatment than as a communicative gesture from clinicians, something done to convey care, manage perceived risk, or assert authority when emotions ran high.23Journal of Applied Social Science. “Another Problem, Another Pill”: Analysing Lived Experience Crisis Accounts of Psychiatric Drug Treatment for People Diagnosed with “Borderline Personality Disorder” That experience of being medicated “at” rather than treated “with” is worth taking seriously, because it affects whether people stay engaged with their care.
Deprescribing and the Role of Skills Training
Given the weak evidence base and the real risks, a growing movement advocates for deliberate medication reduction in BPD, borrowing the concept of “deprescribing” from geriatric medicine. The idea is to systematically review each medication’s risks and benefits, keep the patient’s preferences central to every decision, and hold repeated conversations over time to revisit choices as symptoms change.24PubMed. Collaborative Deprescribing in Borderline Personality Disorder: A Narrative Review
One of the more interesting findings in this area comes from a study that tested whether teaching BPD patients specific coping skills could actually reduce their medication burden. Patients who went through a dialectical behavior therapy skills training group showed a significant reduction in the number of medications they were taking, including drops in benzodiazepine, mood stabilizer, and antipsychotic use. The control group, by contrast, saw no such reduction.25PubMed Central. “Skills for pills”: The dialectical-behavioural therapy skills training reduces polypharmacy in borderline personality disorder The implication is that when people gain concrete skills for managing emotional crises, they need fewer chemical tools to get through them. This aligns with the broader consensus that BPD-specific psychotherapy, not medication, should be the primary treatment, and that medication should be considered only as an adjunct.26PubMed Central. Pharmacological Management of Borderline Personality Disorder and Common Comorbidities
Experimental and Emerging Approaches
Researchers have been exploring several directions beyond the standard drug classes, though none are close to clinical use for BPD specifically.
Omega-3 fatty acids have attracted attention as a low-risk supplement that may complement other treatments. Available data suggest that marine omega-3s can improve impulsive behavioral problems, affective dysregulation, and depressive symptoms in BPD, and may reduce suicidal tendencies.27PubMed Central. Effectiveness of Omega-3 polyunsaturated fatty acids reducing severe symptoms in patients diagnosed with Borderline Personality Disorder (BPD) A follow-up study found that combining omega-3s with valproic acid outperformed valproic acid alone on measures of impulsivity, anger outbursts, and self-harm.28PubMed. Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study The evidence is still limited, but the favorable safety profile makes omega-3s one of the more pragmatic options to discuss with a clinician.
Intranasal oxytocin is a more speculative prospect. A narrative review found that it appears beneficial for emotional regulation and interpersonal sensitivity, particularly in people with early childhood trauma.29PubMed Central. The Promise of Intranasal Oxytocin in Treating Borderline Personality Disorder: A Narrative Review But the picture is not straightforward. In one study, oxytocin actually lowered trust in BPD patients rather than enhancing it, and this effect was correlated with the severity of childhood trauma.30PubMed. Modulation of interpersonal trust in borderline personality disorder by intranasal oxytocin and childhood trauma The idea that a “trust hormone” might reduce trust in traumatized individuals is a good reminder of why BPD pharmacology resists simple solutions.
N-acetylcysteine (NAC), an inexpensive supplement with antioxidant properties, has been tested in a small open-label pilot study for adolescents with nonsuicidal self-injury, a behavior closely associated with BPD features. NAC was linked to a significant decrease in self-injury frequency, as well as reductions in depression scores and overall psychopathology, though not in impulsivity.31PubMed Central. N-Acetylcysteine for Nonsuicidal Self-Injurious Behavior in Adolescents: An Open-Label Pilot Study Without a placebo group, it is impossible to know how much of that improvement was pharmacological versus natural recovery, but it is a thread worth following.
Adolescents and the Medication Question
BPD symptoms often emerge in adolescence, which raises a separate set of medication questions. The diagnosis itself remains controversial in younger people, and the evidence base for medication is even thinner than in adults. A review of therapeutic interventions in adolescents with BPD noted that while low-certainty evidence supports some pharmacological benefit in adults, adolescents with BPD may still need medication primarily for co-occurring conditions like ADHD, depression, or anxiety disorders rather than for BPD itself.32PubMed Central. Therapeutic and Preventive Interventions in Adolescents with Borderline Personality Disorder: Recent Findings, Current Challenges, and Future Directions The concern about prescribing psychotropics to adolescents is amplified when the diagnosis is uncertain and the drugs lack strong evidence even in the adult population they were originally studied in.
The Economic Side of Overmedication
BPD is an expensive condition to live with and to treat. A comprehensive evaluation of societal costs found that the average annual cost per person with BPD was roughly €35,000, nearly six times higher than for people without severe psychological complaints. About 91 percent of those costs were attributed to psychological problems.33PubMed Central. Burden of Disease of Borderline Personality Disorder: A Comprehensive Evaluation of Quality of Life and Societal Cost of Illness Medication costs are only a fraction of this total, which includes lost productivity, hospitalizations, and other healthcare use. But the prescribing patterns contribute to the burden in indirect ways: when people are overmedicated, side effects can interfere with work, education, and the psychotherapy that is most likely to produce lasting improvement. Reducing unnecessary medications is not just a clinical goal but an economic one.